Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Am J Gastroenterol. 2020 May;115(5):746–755. doi: 10.14309/ajg.0000000000000573

Table 2.

Risk of all-cause and cause specific mortality in patients with IBS and matched general population comparators

All-cause mortality CVD Cancer Psychiatric disease
IBS Comparators IBS Comparators IBS Comparators IBS Comparators
N 45 254 217 316 45 254 217 316 45 254 217 316 45 254 217 316
Deaths, no (%) 3290 (7.3%) 13255 (6.1%) 1511 (3.3%) 6079 (2.8%) 1058 (2.3%) 4147 (1.9%) 346 (0.8%) 1759 (0.8%)
Follow-up years
 Mean (SD) 7.7 (4.1) 7.7 (4.1) 6.8 (4.0) 6.8 (4.0) 6.8 (4.0) 6.8 (4.0) 6.8 (4.0) 6.8 (4.0)
 Median (IQR) 7.3 (4.3-10.9) 7.3 (4.3-10.9) 6.4 (3.4-10.0) 6.4 (3.4-10.0) 6.4 (3.4-10.0) 6.4 (3.4-10.0) 6.4 (3.4-10.0) 6.4 (3.4-10.0)
Incidence rate per 1000 PY (95% CI) 9.4 (9.1-9.7) 7.9 (7.8-8.0) 4.9 (4.7-5.1) 4.1 (4.0-4.2) 3.4 (3.2-3.6) 2.8 (2.7-2.9) 1.1 (1.0-1.2) 1.2 (1.1-1.2)
Hazard ratio (95% CI)
 Unadjusted 1.19 (1.15-1.24) 1.19 (1.13-1.26) 1.22 (1.14-1.31) 0.94 (0.84-1.06)
 Conditioned 1.10 (1.05-1.14) 1.06 (1.00-1.13) 1.16 (1.08-1.24) 0.84 (0.74-0.95)
 Adjusted I 1.12 (1.08-1.17) 1.09 (1.03-1.16) 1.18 (1.10-1.26) 0.87 (0.77-0.98)
 Adjusted II 0.96 (0.92-1.00) 0.92 (0.87-0.98) 0.93 (0.86-1.00) 0.81 (0.71-0.92)

Conditioned: Conditioned on age, sex, county, and calendar period;

Adjusted I: Conditioned and further adjusted for level of education;

Adjusted II: Adjusted I and further adjusted for baseline medical comorbidities (cancer, diabetes, CVD, and neurologic disease)

IBS, irritable bowel syndrome; CVD, cardiovascular disease; SD, standard deviation; IQR, interquartile range